Welcome.
Are you a healthcare professional?

This website contains promotional information for Chiesi's respiratory products, and is intended solely for UK healthcare professionals. Please confirm below, or go back to the home page.

UK-RES-2000248 Feb 2020

You are now leaving Chiesi's website

By clicking this link, you will be taken to a website that is not owned or controlled by Chiesi. Chiesi is not responsible for the content provided on that site.

Continue
Go back

UK-RES-2000003 Jan 2020

INTENDED FOR UK HEALTHCARE PROFESSIONALS
Fostair® logo (beclometasone/formoterol) Extrafine formulation 100/6 & 200/6
Background

The Fostair Family

trimbow_subheader-mobile

The only extrafine formulation ICS/LABA combination1–5

Designed to reach the large and small airways1–4,6

2 devices, 2 strengths, 2 indications1–4

  • Fostair 100/6 is indicated for adult asthma and COPD (FEV1 <50% predicted normal)1,3
  • Fostair 100/6 can also be used for Maintenance and Reliever Therapy (MART) for asthma in adults1,3
  • Fostair 200/6 is indicated for asthma in adults2,4

The only ICS/LABA fixed-dose combination licensed in asthma and COPD in both pressurised metered dose inhalers (pMDI) and dry powder inhalers (DPI).1,3 Fostair (beclometasone and formoterol) is available in 100/6 and 200/6 formulations.1-4
 

Fostair® NEXThaler and pMDI device images for 100/6 & 200/6
Indications
Fostair® NEXThaler and pMDI devices 100/6

Fostair 100/61,3

Available in both pMDI and NEXThaler DPI

  • Adult asthma
  • Maintenance and Reliever Therapy (MART)
  • COPD (FEV1 <50% predicted normal)
Fostair® NEXThaler and pMDI devices 200/6

Fostair 200/62,4

Available in both pMDI and NEXThaler DPI

  • Adult asthma
For additional information to share with your patients who have been prescribed Fostair NEXThaler or Fostair pMDI please visit our Fostair NEXThaler patient and carer site or Fostair pMDI patient and carer site.

Click here for Fostair® (beclometasone/formoterol) Prescribing Information.

COPD: chronic obstructive pulmonary disease; DPI: dry powder inhaler; FEV1: forced expiratory volume in 1 second; ICS: inhaled corticosteroid; LABA: long-acting β2-agonist; MART: maintenance and reliever therapy; pMDI: pressurised metered dose inhaler.

References:
1. Fostair NEXThaler 100/6 Summary of Product Characteristics. Chiesi Limited.
2. Fostair NEXThaler 200/6 Summary of Product Characteristics. Chiesi Limited.
3. Fostair pMDI 100/6 Summary of Product Characteristics. Chiesi Limited.
4. Fostair pMDI 200/6 Summary of Product Characteristics. Chiesi Limited.
5. MIMS online. 2020. Available at: https://www.mims.co.uk/. Accessed: June 2020.
6. Singh D. Tuberc Respir Dis. 2017; 80: 317–324.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Chiesi Ltd on 0800 0092329 (UK), 1800 817459 (IE) PV.UK@Chiesi.com.